{
    "clinical_study": {
        "@rank": "142747", 
        "arm_group": [
            {
                "arm_group_label": "RO6811135", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized, double-blind, placebo-controlled study will evaluate the safety,\n      tolerability, pharmacokinetics and pharmacodynamics of RO6811135 in healthy volunteers.\n      Subjects will be randomized in cohorts to receive either single ascending doses of RO6811135\n      or placebo subcutaneously."
        }, 
        "brief_title": "A Study of Single Dose RO6811135 in Healthy Volunteers", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteer", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male and female volunteers, 18 to 45 years of age inclusive\n\n          -  Body mass index (BMI) 22-32 kg/m2 inclusive\n\n          -  Females of child-bearing potential and males with female partners of child-bearing\n             potential must agree to use adequate contraception as defined by protocol\n\n        Exclusion Criteria:\n\n          -  History or presence of any clinically relevant disease or disorder\n\n          -  History of drug hypersensitivity or food allergies\n\n          -  Significant infection or known inflammatory process at screening or Day -1\n\n          -  Any history of alcohol and/or drug of abuse addiction\n\n          -  Alcohol consumption of more than 14 units (1 unit = 10 mL of pure alcohol) per week\n\n          -  Smoking more than 5 cigarettes a day or equivalent amount of tobacco\n\n          -  Positive for hepatitis B, hepatitis C or HIV infection\n\n          -  Participation in an investigational drug or device study within 3 months prior to\n             screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "56", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01676584", 
            "org_study_id": "BP28410"
        }, 
        "intervention": [
            {
                "arm_group_label": "RO6811135", 
                "description": "single ascending doses sc", 
                "intervention_name": "RO6811135", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "single doses sc", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Cincinnati", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "45227"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Placebo-controlled Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO6811135 in Healthy Subjects.", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Safety: Incidence of adverse events", 
            "safety_issue": "No", 
            "time_frame": "approximately 3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01676584"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetics: Area under the concentration-time curve", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose and up to 96 hours post-dose"
            }, 
            {
                "measure": "Pharmacodynamics (blood analysis) of RO6811135", 
                "safety_issue": "No", 
                "time_frame": "96 hours"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}